MA40368A - Traitement de tumeurs stromales gastro-intestinales (tsgi) - Google Patents
Traitement de tumeurs stromales gastro-intestinales (tsgi)Info
- Publication number
- MA40368A MA40368A MA040368A MA40368A MA40368A MA 40368 A MA40368 A MA 40368A MA 040368 A MA040368 A MA 040368A MA 40368 A MA40368 A MA 40368A MA 40368 A MA40368 A MA 40368A
- Authority
- MA
- Morocco
- Prior art keywords
- gist
- therapy
- alpha
- pdgfr
- pdgfr alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne les anticorps humains qui se lient au récepteur alpha du facteur de croissance dérivé des plaquettes (pdgfr alpha) humain, de préférence l'olaratumab, pour le traitement de tumeurs stromales gastro-intestinales présentant des mutations de pdgfr alpha, notamment la mutation d842v.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462020429P | 2014-07-03 | 2014-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40368A true MA40368A (fr) | 2017-05-10 |
Family
ID=53514438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040368A MA40368A (fr) | 2014-07-03 | 2015-06-26 | Traitement de tumeurs stromales gastro-intestinales (tsgi) |
Country Status (9)
Country | Link |
---|---|
US (1) | US20170137523A1 (fr) |
EP (1) | EP3164416A1 (fr) |
JP (1) | JP6480479B2 (fr) |
CN (1) | CN106714832A (fr) |
CA (1) | CA2950946A1 (fr) |
MA (1) | MA40368A (fr) |
MX (1) | MX2016016866A (fr) |
TW (1) | TWI619728B (fr) |
WO (1) | WO2016003797A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018169779A1 (fr) * | 2017-03-17 | 2018-09-20 | ImClone, LLC | Polythérapie pour le traitement du cancer du pancréas |
CN109535243B (zh) * | 2019-01-07 | 2019-09-24 | 北京诺思兰德生物技术股份有限公司 | 人肝细胞生长因子突变体及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1316263A (en) * | 1919-09-16 | Train-control system | ||
WO2003105773A2 (fr) * | 2002-06-01 | 2003-12-24 | Oregon Health & Science University | Mutations d'activation de pdgfra (platelet derived growth factor receptor alpha) servant de marqueurs diagnostiques et cibles therapeutiques |
KR20080047529A (ko) | 2005-06-17 | 2008-05-29 | 임클론 시스템즈 인코포레이티드 | 전이성 골암 치료를 위한 수용체 길항제 |
US20150152474A1 (en) * | 2012-03-09 | 2015-06-04 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
CN102719530B (zh) * | 2012-05-07 | 2013-11-06 | 厦门艾德生物医药科技有限公司 | 一种用于检测PDGFRα基因突变的引物、探针及试剂盒 |
-
2015
- 2015-06-26 WO PCT/US2015/037970 patent/WO2016003797A1/fr active Application Filing
- 2015-06-26 TW TW104120840A patent/TWI619728B/zh not_active IP Right Cessation
- 2015-06-26 JP JP2016575333A patent/JP6480479B2/ja not_active Expired - Fee Related
- 2015-06-26 CN CN201580033774.7A patent/CN106714832A/zh active Pending
- 2015-06-26 EP EP15734541.4A patent/EP3164416A1/fr not_active Withdrawn
- 2015-06-26 MA MA040368A patent/MA40368A/fr unknown
- 2015-06-26 US US15/318,376 patent/US20170137523A1/en not_active Abandoned
- 2015-06-26 MX MX2016016866A patent/MX2016016866A/es unknown
- 2015-06-26 CA CA2950946A patent/CA2950946A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3164416A1 (fr) | 2017-05-10 |
TWI619728B (zh) | 2018-04-01 |
WO2016003797A1 (fr) | 2016-01-07 |
US20170137523A1 (en) | 2017-05-18 |
TW201612192A (en) | 2016-04-01 |
MX2016016866A (es) | 2017-04-25 |
CA2950946A1 (fr) | 2016-01-07 |
JP2017524681A (ja) | 2017-08-31 |
CN106714832A (zh) | 2017-05-24 |
JP6480479B2 (ja) | 2019-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
MX2017008819A (es) | Anticuerpos anti-cd47 y usos de los mismos. | |
MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
TW201613648A (en) | Compounds and compositions for immunotherapy | |
MX2017007941A (es) | Anticuerpos antagonistas anti-axl. | |
MX2016012371A (es) | Anticuerpos multiespecificos. | |
MX369623B (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
MX2016016886A (es) | Anticuerpos anti-axl. | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
MX2016014862A (es) | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. | |
EA201791421A1 (ru) | Антитела против csf1r для лечения pvns | |
MX370897B (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades,. | |
EA201692482A1 (ru) | Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) | |
TW201612192A (en) | Therapy for GIST | |
MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
TW201611844A (en) | Combination therapy |